ALTER Stock Overview
Theradiag SA develops, manufactures, and markets in-vitro diagnostic products.
Price History & Performance
|Historical stock prices|
|Current Share Price||€2.30|
|52 Week High||€2.75|
|52 Week Low||€1.31|
|1 Month Change||51.12%|
|3 Month Change||39.39%|
|1 Year Change||21.05%|
|3 Year Change||124.39%|
|5 Year Change||-8.00%|
|Change since IPO||-59.36%|
Recent News & Updates
|ALTER||FR Medical Equipment||FR Market|
Return vs Industry: ALTER exceeded the French Medical Equipment industry which returned -20.1% over the past year.
Return vs Market: ALTER exceeded the French Market which returned -12.3% over the past year.
|ALTER Average Weekly Movement||17.4%|
|Medical Equipment Industry Average Movement||6.4%|
|Market Average Movement||4.9%|
|10% most volatile stocks in FR Market||9.3%|
|10% least volatile stocks in FR Market||2.8%|
Stable Share Price: ALTER is more volatile than 90% of French stocks over the past 3 months, typically moving +/- 17% a week.
Volatility Over Time: ALTER's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of French stocks.
About the Company
|1986||60||Bertrand De Castelnau||https://www.theradiag.com|
Theradiag SA develops, manufactures, and markets in-vitro diagnostic products. It offers autoimmunity reagents; IMMUNO-TROL, a multi-parametric quality control tool; various instruments for autoimmunity and infectious diseases testing; SQA-V system, a semen analyzer; and V-Sperm for loading results, pictures, and videos of the samples into the computer. The company also provides instrumentation, including Theralis that integrates multiplex FIDIS immunofluorescence and ELISA; Theralis µ, a solution for medium sized laboratories; and FIDIS platform used in laboratory for analysis.
Theradiag Fundamentals Summary
|ALTER fundamental statistics|
Is ALTER overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ALTER income statement (TTM)|
|Cost of Revenue||€7.91m|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.056|
|Net Profit Margin||-5.72%|
How did ALTER perform over the long term?See historical performance and comparison
Is ALTER undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 2/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for ALTER?
Other financial metrics that can be useful for relative valuation.
|What is ALTER's n/a Ratio?|
Price to Sales Ratio vs Peers
How does ALTER's PS Ratio compare to its peers?
|ALTER PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
MKEA Mauna Kea Technologies
ALDMS Diagnostic Medical Systems
Price-To-Sales vs Peers: ALTER is good value based on its Price-To-Sales Ratio (2.3x) compared to the peer average (12.9x).
Price to Earnings Ratio vs Industry
How does ALTER's PE Ratio compare vs other companies in the FR Medical Equipment Industry?
Price-To-Sales vs Industry: ALTER is good value based on its Price-To-Sales Ratio (2.3x) compared to the French Medical Equipment industry average (2.6x)
Price to Sales Ratio vs Fair Ratio
What is ALTER's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||2.3x|
|Fair PS Ratio||0.9x|
Price-To-Sales vs Fair Ratio: ALTER is expensive based on its Price-To-Sales Ratio (2.3x) compared to the estimated Fair Price-To-Sales Ratio (0.9x).
Share Price vs Fair Value
What is the Fair Price of ALTER when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate ALTER's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate ALTER's fair value for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
How is Theradiag forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Future Growth Score3/6
Future Growth Score 3/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ALTER is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.3%).
Earnings vs Market: ALTER is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: ALTER is expected to become profitable in the next 3 years.
Revenue vs Market: ALTER's revenue (5.2% per year) is forecast to grow slower than the French market (5.3% per year).
High Growth Revenue: ALTER's revenue (5.2% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ALTER's Return on Equity is forecast to be low in 3 years time (3.3%).
Discover growth companies
How has Theradiag performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ALTER is currently unprofitable.
Growing Profit Margin: ALTER is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ALTER is unprofitable, but has reduced losses over the past 5 years at a rate of 56.3% per year.
Accelerating Growth: Unable to compare ALTER's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ALTER is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (-1.9%).
Return on Equity
High ROE: ALTER has a negative Return on Equity (-8.24%), as it is currently unprofitable.
Discover strong past performing companies
How is Theradiag's financial position?
Financial Health Score3/6
Financial Health Score 3/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: ALTER's short term assets (€10.7M) exceed its short term liabilities (€2.4M).
Long Term Liabilities: ALTER's short term assets (€10.7M) exceed its long term liabilities (€3.1M).
Debt to Equity History and Analysis
Debt Level: ALTER has more cash than its total debt.
Reducing Debt: ALTER's debt to equity ratio has increased from 0.9% to 21.8% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Insufficient data to determine if ALTER has enough cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if ALTER has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Discover healthy companies
What is Theradiag current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
|Theradiag Dividend Yield vs Market|
|Market Bottom 25% (FR)||2.0%|
|Market Top 25% (FR)||6.1%|
|Industry Average (Medical Equipment)||1.8%|
|Analyst forecast in 3 Years (Theradiag)||n/a|
Notable Dividend: Unable to evaluate ALTER's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ALTER's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ALTER's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ALTER's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as ALTER has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Bertrand De Castelnau (61 yo)
Mr. Bertrand de Castelnau serves as Chief Executive Officer at Theradiag SA since December 11, 2018 and served as its Director since February 04, 2019 and served as its Managing Director until 2022. He beg...
Experienced Board: ALTER's board of directors are not considered experienced ( 0.6 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
|Owner Type||Number of Shares||Ownership Percentage|
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 50.2%.
|Ownership||Name||Shares||Current Value||Change %||Portfolio %|
Theradiag SA's employee growth, exchange listings and data sources
- Name: Theradiag SA
- Ticker: ALTER
- Exchange: ENXTPA
- Founded: 1986
- Industry: Health Care Equipment
- Sector: Healthcare
- Implied Market Cap: €29.930m
- Shares outstanding: 13.01m
- Website: https://www.theradiag.com
Number of Employees
- Theradiag SA
- 14 rue Ambroise Croizat
- CS 90136 Croissy Beaubourg
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|ALTER||ENXTPA (Euronext Paris)||Yes||Common Stock||FR||EUR||Dec 2012|
|4W6||BST (Boerse-Stuttgart)||Yes||Common Stock||DE||EUR||Dec 2012|
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/10/02 00:00|
|End of Day Share Price||2022/09/30 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.